| Literature DB >> 29450182 |
Hiroki Ikenaga1, Satoshi Kurisu1, Noriaki Watanabe1, Takashi Shimonaga1, Tadanao Higaki1, Toshitaka Iwasaki1, Hiroto Utsunomiya1, Naoya Mitsuba1, Ken Ishibashi1, Yoshihiro Dohi1, Yukihiro Fukuda1, Katsuhiko Imai2, Taijiro Sueda2, Yasuki Kihara1.
Abstract
BACKGROUND: Both aortic aneurysms and coronary artery ectasia (CAE) frequently coexist and are associated with more pronounced inflammation. Neutrophil to lymphocyte ratio (NL ratio) is widely used as a marker of inflammation. However, relation between CAE and NL ratio in patients with aortic aneurysms is not fully understood. This study was undertaken to assess relation between CAE and NL ratio in patients with aortic aneurysms.Entities:
Keywords: Aortic aneurysms; Coronary artery ectasia; Neutrophil to lymphocyte ratio
Year: 2014 PMID: 29450182 PMCID: PMC5801477 DOI: 10.1016/j.ijchv.2014.08.002
Source DB: PubMed Journal: Int J Cardiol Heart Vessel ISSN: 2214-7632
Baseline characteristics between the patients with AA and those without AA.
| AA group | Control group | p value | |
|---|---|---|---|
| Age (years) | 72.8 ± 8.8 | 67.1 ± 10.9 | < 0.001 |
| Male | 75 (80.7%) | 55 (69.6%) | 0.09 |
| Hypertension | 77 (82.8%) | 55 (69.6%) | 0.04 |
| Dyslipidemia | 41 (44.1%) | 41 (51.9%) | 0.31 |
| Diabetes mellitus | 17 (18.3%) | 28 (35.4%) | 0.01 |
| Current smoker | 28 (30.1%) | 23 (29.1%) | 0.87 |
| Body mass index (kg/m2) | 23.4 ± 4.0 | 24.1 ± 3.7 | 0.28 |
| Previous MI | 6 (6.5%) | 0 (0%) | 0.02 |
| Atrial fibrillation | 9 (9.7%) | 5 (6.3%) | 0.42 |
| Medication | |||
| Aspirin | 28 (30.1%) | 19 (24.1%) | 0.37 |
| β-Blocker | 28 (30.1%) | 16 (20.3%) | 0.13 |
| Ca-blocker | 51 (54.8%) | 41 (51.9%) | 0.70 |
| ACE-I/ARB | 56 (60.2%) | 36 (45.6%) | 0.06 |
| Statin | 28 (30.1%) | 23 (29.1%) | 0.43 |
| Diuretic | 11 (11.8%) | 12 (15.2%) | 0.52 |
| LVEF (%) | 60.4 ± 7.8 | 61.7 ± 7.2 | 0.16 |
| White blood cell (103/μl) | 6721 ± 2258 | 6396 ± 2121 | 0.30 |
| NL ratio | 2.93 ± 1.43 | 2.45 ± 1.05 | 0.027 |
| Hemoglobin (g/dl) | 12.95 ± 2.07 | 13.42 ± 1.90 | 0.11 |
| Hematocrit (%) | 38.33 ± 5.70 | 39.58 ± 5.11 | 0.13 |
| C-reactive protein (mg/dl) | 1.03 ± 2.97 | 0.19 ± 0.29 | < 0.01 |
| Platelet (mm3/μl) | 187.30 ± 62.26 | 200.29 ± 66.37 | 0.48 |
| eGFR (ml/min per 1.73 m2) | 61.02 ± 22.78 | 65.80 ± 28.74 | 0.08 |
| eGFR < 60 ml/min per 1.73 m2 | 41 (44.1%) | 28 (35.4%) | 0.25 |
| HDL cholesterol (mg/dl) | 50.9 ± 14.3 | 57.6 ± 22.1 | 0.054 |
| LDL cholesterol (mg/dl) | 110.4 ± 28.9 | 110.1 ± 44.1 | 0.40 |
| Triglyceride (mg/dl) | 133.9 ± 64.1 | 147.2 ± 127.9 | 0.78 |
| HbA1c (%) | 5.92 ± 0.52 | 6.24 ± 1.45 | 0.63 |
| D-dimer (μg/ml) | 6.73 ± 7.67 | 1.03 ± 1.59 | < 0.01 |
MI; myocardial infarction, ACE-I; angiotensin-converting enzyme inhibitor, ARB; angiotensin II receptor blocker, LVEF; left ventricular ejection fraction, NL ratio; neutrophil to lymphocyte ratio, eGFR; estimated glomerular filtration rate, HDL; high-density lipoprotein, LDL; low-density lipoprotein, HbA1c; hemoglobin A1c. P values were two-tailed, and p < 0.05 was considered as statistically significant.
Angiographic characteristics between the patients with AA and those without AA.
| AA group | Control group | |
|---|---|---|
| Coronary stenosis | 43 (46.2%) | – |
| LMCA stenosis | 8 (8.6%) | – |
| LAD stenosis | 16 (17.2%) | – |
| LCX stenosis | 13 (14.0%) | – |
| RCA stenosis | 26 (28.0%) | – |
| CAD severity | ||
| 1-Vessel disease | 25 (26.9%) | – |
| 2-Vessel disease | 11 (11.9%) | – |
| 3-Vessel disease | 7 (7.5%) | – |
| Coronary ectasia | 44 (47.3%) | – |
| LAD ectasia | 30 (32.6%) | – |
| Diffuse | 17 (18.5%) | – |
| LCX ectasia | 24 (26.1%) | – |
| Diffuse | 21 (22.8%) | – |
| RCA ectasia | 32 (34.8%) | – |
| Diffuse | 29 (31.5%) | – |
LMCA = left main coronary artery, LAD = left anterior descending coronary artery, LCX = left circumflex coronary artery, RCA = right coronary artery, CAD = coronary artery disease.
Baseline characteristics between the patients with CAE and those without CAE in the AA group.
| CAE (+) group | CAE (−) group | p value | |
|---|---|---|---|
| Ascending thoracic aneurysms | 11 (25.0%) | 19 (38.8%) | 0.15 |
| Age (years) | 72.5 ± 9.8 | 73.2 ± 8.0 | 0.92 |
| Male | 36 (81.8%) | 39 (79.6%) | 0.79 |
| Hypertension | 39 (88.6%) | 38 (77.6%) | 0.15 |
| Dyslipidemia | 21 (47.7%) | 20 (40.8%) | 0.50 |
| Diabetes mellitus | 7 (15.9%) | 10 (20.4%) | 0.31 |
| Current smoker | 11 (25.0%) | 17 (34.7%) | 0.87 |
| Body mass index (kg/m2) | 23.7 ± 3.7 | 23.1 ± 3.7 | 0.50 |
| Previous MI | 3 (6.8%) | 3 (6.1%) | 0.89 |
| Atrial fibrillation | 6 (13.6%) | 3 (6.1%) | 0.22 |
| Medication | |||
| Aspirin | 15 (34.1%) | 13 (26.5%) | 0.43 |
| β-Blocker | 18 (40.9%) | 10 (20.4%) | 0.03 |
| Ca-blocker | 28 (63.6%) | 23 (46.9%) | 0.11 |
| ACE-I/ARB | 31 (70.5%) | 25 (51.0%) | 0.06 |
| Statin | 24 (54.6%) | 18 (36.7%) | 0.08 |
| Diuretic | 5 (11.4%) | 6 (12.2%) | 0.90 |
| LVEF (%) | 60.0 ± 6.9 | 60.1 ± 8.6 | 0.55 |
| White blood cell (103/μl) | 7149 ± 1937 | 6338 ± 2469 | 0.04 |
| NL ratio | 3.39 ± 1.67 | 2.52 ± 1.04 | < 0.01 |
| Hemoglobin (g/dl) | 13.25 ± 2.12 | 12.68 ± 2.00 | 0.21 |
| Hematocrit (%) | 39.27 ± 5.69 | 37.51 ± 5.65 | 0.13 |
| C-reactive protein (mg/dl) | 1.39 ± 4.01 | 0.72 ± 1.53 | 0.99 |
| Platelet (mm3/μl) | 197.71 ± 59.91 | 177.96 ± 63.44 | 0.12 |
| eGFR (ml/min per 1.73 m2) | 60.60 ± 26.83 | 61.39 ± 18.68 | 0.94 |
| eGFR < 60 ml/min per 1.73 m2 | 17 (38.6%) | 24 (50.0%) | 0.32 |
| HDL cholesterol (mg/dl) | 48.4 ± 13.1 | 53.2 ± 15.1 | 0.12 |
| LDL cholesterol (mg/dl) | 113.9 ± 28.4 | 107.1 ± 29.4 | 0.35 |
| Triglyceride (mg/dl) | 147.4 ± 61.4 | 121.7 ± 64.6 | 0.02 |
| HbA1c (%) | 6.02 ± 0.46 | 5.85 ± 0.57 | 0.13 |
| D-dimer (μg/ml) | 6.10 ± 7.25 | 7.34 ± 8.12 | 0.42 |
MI; myocardial infarction, ACE-I; angiotensin-converting enzyme inhibitor, ARB; angiotensin II receptor blocker, LVEF; left ventricular ejection fraction, NL ratio; neutrophil to lymphocyte ratio, eGFR; estimated glomerular filtration rate, HDL; high-density lipoprotein, LDL; low-density lipoprotein, HbA1c; hemoglobin A1c. P values were two-tailed, and p < 0.05 was considered statistically significant.
Fig. 1Relation between NL ratio and coronary artery ectasia in patients with aortic aneurysms.
The CAE (+) group had a significantly higher NL ratio than the CAE (−) group (3.39 ± 1.67 vs. 2.52 ± 1.04, p < 0.01).
NL ratio; neutrophil to lymphocyte ratio, CAE; coronary artery ectasia.
Independent predictors of coronary artery ectasia in patients with aortic aneurysms.
| Univariate | p value | Multivariate | p value | |
|---|---|---|---|---|
| White blood cell (103/μl) | 0.99 (0.99–1.01) | 0.79 | ||
| NL ratio | 1.65 (1.18–2.44) | 0.002 | 1.76 (1.24–2.69) | 0.001 |
| Hemoglobin (g/dl) | 1.15 (0.94–1.43) | 0.18 | ||
| Hematocrit (%) | 1.06 (0.83–1.15) | 0.13 | ||
| C-reactive protein (mg/dl) | 1.09 (0.94–1.37) | 0.26 | ||
| Platelet (mm3/μl) | 1.00 (0.99–1.02) | 0.12 | ||
| eGFR (ml/min per 1.73 m2) | 0.99 (0.98–1.02) | 0.86 | ||
| eGFR < 60 ml/min per 1.73 m2 | 1.52 (0.28–1.64) | 0.32 | ||
| HDL cholesterol (mg/dl) | 0.98 (0.94–1.01) | 0.09 | 0.99 (0.95–1.02) | 0.50 |
| LDL cholesterol (mg/dl) | 1.00 (0.99–1.02) | 0.26 | ||
| Triglyceride (mg/dl) | 1.01 (1.01–1.02) | 0.049 | 1.00 (0.99–1.01) | 0.07 |
| HbA1c (%) | 1.91 (0.83–5.01) | 0.13 | ||
| D-dimer (μg/ml) | 0.98 (0.92–1.01) | 0.49 | ||
| After adjustment for propensity scores | ||||
| NL ratio | 1.56 (1.10–2.40) | 0.01 |
OR; odds ratio, CI; confidence interval, NL ratio; neutrophil to lymphocyte ratio, eGFR; estimated glomerular filtration rate, HDL; high-density lipoprotein, LDL; low-density lipoprotein, HbA1c; hemoglobin A1c.
Adjusted for ascending thoracic aneurysms, age, male, hypertension, dyslipidemia, diabetes mellitus, current smoker, body mass index, previous myocardial infarction, atrial fibrillation, left ventricular ejection fraction, use of aspirin, β-blocker, Ca-blocker, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, statin and diuretic.